Oncolytics Biotech Inc
TSX:ONC
Oncolytics Biotech Inc
TSX:ONC
Price:
1.62 CAD
0.62%
Market Closed
Updated:
May 8, 2024
Oncolytics Biotech Inc
Operating Income
|
Oncolytics Biotech Inc
Operating Income Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
EDT
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Oncolytics Biotech Inc
TSX:ONC
|
Operating Income
-CA$33.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-4%
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Operating Income
-$138.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Operating Income
-$116.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Operating Income
-$99.2m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Operating Income
-$68.7m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-25%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Operating Income
-CA$11.7m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
0%
|
See Also
What is Oncolytics Biotech Inc's Operating Income?
Operating Income
-33.8m
CAD
-33.8m
CAD
Based on the financial report for Dec 31, 2023, Oncolytics Biotech Inc's Operating Income amounts to -33.8m CAD.
What is Oncolytics Biotech Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-4%
-4%
Over the last year, the Operating Income growth was -26%. The average annual Operating Income growth rates for Oncolytics Biotech Inc have been -10% over the past three years , -14% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
